CoChat

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

Open access
Moretto, Roberto, Cremolini, Chiara, Rossini, Daniele, Pietrantonio, Filippo, Battaglin, Francesca, Mennitto, Alessia, Bergamo, Francesca, Loupakis, Fotios, Marmorino, Federica, Berenato, Rosa, Marsico, Valentina Angela, Caporale, Marta, Antoniotti, Carlotta, Masi, Gianluca, Salvatore, Lisa, Borelli, Beatrice, Fontanini, Gabriella, Lonardi, Sara, De Braud, Filippo, Falcone, Alfredo · 2016 · The Oncologist
Cited by 101

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Introduction.: Right- and left-sided colorectal cancers (CRCs) differ in clinical and molecular characteristics. Some retrospective analyses suggested that patients with right-sided tumors derive less benefit from anti-epidermal growth factor receptor (EGFR) antibodies; however, molecular selection in those studies was not extensive. Patients and Methods.: Patients with RAS and BRAF wild-type metastatic CRC (mCRC) who were treated with single-agent anti-EGFRs or with cetuximab-irinotecan (if refractory to previous irinotecan) were included in the study. Differences in outcome between patients with right- and left-sided tumors were investigated. Results.: Of 75 patients, 14 and 61 had right- and left-sided tumors, respectively. None of the right-sided tumors responded according to RECIST, compared with 24 left-sided tumors (overall response rate: 0% vs. 41%; p = .0032), and only 2 patients with right-sided tumors (15%) versus 47 patients with left-sided tumors (80%) achieved disease control (p < .0001). The median duration of progression-free survival was 2.3 and 6.6 months in patients with right-sided and left-sided tumors, respectively (hazard ratio: 3.97; 95% confidence interval: 2.09–7.53; p < .0001). Conclusion.: Patients with right-sided RAS and BRAF wild-type mCRC seemed to derive no benefit from single-agent anti-EGFRs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2016-0084

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 101

Metadata

Authors
Moretto, R., Cremolini, C., Rossini, D., Pietrantonio, F., Battaglin, F., Mennitto, A., Bergamo, F., Loupakis, F., Marmorino, F., Berenato, R., Marsico, V. A., Caporale, M., Antoniotti, C., Masi, G., Salvatore, L., Borelli, B., Fontanini, G., Lonardi, S., De Braud, F., & Falcone, A.
Venue
The Oncologist
Published
2016-07-05
Volume
21
Issue
8
Pages
988-994
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2468717730
Cited by
101
References
3
FWCI
6.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1634/theoncologist.2016-0084
The paper
Moretto, R., Cremolini, C., Rossini, D., Pietrantonio, F., Battaglin, F., Mennitto, A., Bergamo, F., Loupakis, F., Marmorino, F., Berenato, R., Marsico, V. A., Caporale, M., Antoniotti, C., Masi, G., Salvatore, L., Borelli, B., Fontanini, G., Lonardi, S., De Braud, F., & Falcone, A. (2016). Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. The Oncologist. https://doi.org/10.1634/theoncologist.2016-0084

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.